Stanford seems to have found a niche in tiny wireless implants. In the latest development, the university announced that it is developing methods of beaming ultrasound to power implanted "smart chips" for the treatment of conditions like Parkinson's disease.
Investigators at the University of California, Los Angeles, have found that a drug being studied for a rare genetic disorder called Gaucher disease also appears to slow the progression of Parkinson's disease in mice.
Israel's NeuroDerm filed for a stock offering on the basis of its subcutaneous formulation for treating Parkinson's; Civitas, the developer of an inhaled formulation for the disease, is expected to debut on the Nasdaq Sept. 24; and EyeGate Pharmaceuticals, which employs low-voltage electrical current to deliver eye medication, also just filed for an IPO.
Israel's NeuroDerm is developing a wearable treatment solution for patients with Parkinson's disease, and the biotech is plotting a $65 million IPO to get its lead candidates across the finish line.
Researchers are applying the full range of mobile technology to Parkinson's disease diagnostics. This week a pair of new technologies came to the fore, with a wearable device is cleared by FDA and a smartphone app unveiled at the British Science Festival.
Columbia University scientists showed that it is possible to control the size of the blood-brain barrier opening by varying the pressure of an ultrasound beam, a discovery that could herald major breakthroughs in the treatment of neurological diseases.
A couple of major players are making moves to get wearable med tech a bit closer to reality. Intel has partnered with the Michael J. Fox Foundation to collect data via smartwatches on Parkinson's disease patients, tracking the progression of disease.
An experimental anti-inflammatory drug delivered via a shot in the skin prevents neuron loss in rats with Parkinson's disease, according to a new study by researchers from Emory University School of Medicine in Atlanta.
A sublingually delivered thin film strip to treat advanced Parkinson's disease kicked off its Phase II clinical trial following discussions with the FDA, Cynapsus Therapeutics announced July 16.
A chemical switch that controls the transformation of neural stem cells into neurons and keeps existing nerve cells in the brain alive may be a viable target for neurodegenerative disorders such as Alzheimer's, Parkinson's and autism.